|
|
Melatonin Vinpocetine* | |
|
Alcohol Grapefruit juice | |
| Depletion or interference |
None known |
| Side effect reduction/prevention |
None known |
| Reduced drug absorption/bioavailability |
None known |
An asterisk (*) next to an item in the summary indicates that the interaction is supported only by weak, fragmentary, and/or contradictory scientific evidence.
Melatonin
A preliminary study showed that taking melatonin and triazolam together produces better
quality of sleep than occurs when the drug is taken alone. The results also indicated that
less triazolam is needed when melatonin and triazolam are taken together, which might reduce
side effects such as morning grogginess.1 Additional research is needed to
determine whether individuals taking triazolam should also take melatonin.
Vinpocetine
In a preliminary trial, an extract of periwinkle called vinpocetine was shown to produce minor
improvements in short-term memory among people taking flunitrazepam, a
benzodiazepine.2 Further study is needed to determine if vinpocetine would be a
helpful adjunct to use of benzodiazepines, or triazolam specifically.
Grapefruit juice
Drinking grapefruit juice with triazolam dramatically increases the amount of drug absorbed
and the amount of time it stays in the body.3 Though the clinical significance of
this interaction is unknown, some people may experience increased side effects, such as
morning grogginess, dizziness, and poor coordination. Therefore, people taking triazolam
should probably avoid drinking grapefruit juice or eating grapefruit for the duration of
therapy.
Alcohol
Drinking alcoholic beverages while taking triazolam may enhance side effects such as
drowsiness, confusion, and dizziness.4 Consequently, people taking triazolam should
avoid drinking alcohol, especially when they must stay alert.
1. Ferini-Strambi L, Zucconi M, Biella G, et al. Effect of melatonin on sleep microstructure: preliminary results in healthy subjects. Sleep 1993;16:744–7..
2. Bhatti JZ, Hindmarch I. Vinpocetine effects on cognitive impairments produced by flunitrazepam. Int Clin Psychopharmacol 1987;2:325–31.
3. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 2461–3.
4. Sifton DW, ed. Physicians’ Desk Reference. Montvale, NJ: Medical Economics Company, Inc., 2000, 2461–3
| |||||||